Clinical Trials Supply Chain Logistics Global Congress 2015 Europe


Background Info

Clinical Trials Supply Chain Logistics Global Congress 2015 Europe

Paradigm Global Events are proud to present the Clinical Trials Supply Chain Logistics Global Congress 2014 Europe.

The pharmaceutical industry began globalizing clinical trials about 15 years ago and; lured by lower research expenses and rapid patient recruitment half of all clinical trials are conducted offshore and in more developing countries than ever before, profoundly increasing the complexity of supply chain logistics. Some of the forces affecting the industry include access to new markets and patients, regulatory standards for clinical trials supply, supply chain security and other technology for developing and testing medicines.

“The global market for clinical trial supply and logistics services will expand by six percent in 2014, with revenue growth to 2023.??? (Visiongain’s Clinical Trials Supply and Logistics: World Market Outlook 2014 – 2023). Along with this opportunity are challenges and hurdles for the pharmaceutical industry to overcome.

Clinical Trials Supply Chain Logistics Global Congress 2014 – Europe provides a unique platform for an intimate & interactive knowledge sharing and convergence of top tier government, pharmaceuticals, biopharmaceuticals, as well as regional and local manufacturers to discuss the driving macroeconomic factors, policies and issues that will steer the clinical trials supply chain logistics industry.

Gain The Latest Insights on:

  • Economic Outlook: Supply Chain Logistics to Steer Clinical Trials
  • Globalization of Clinical Trials: Opportunities and Challenges
  • Good Distribution Practice (GDP): Increase Demand for Clinical Trials Logistics
  • Costs Explained: Maintaining Safety and Efficacy of Drugs
  • Security Measures: Holistic Supply Chain Security and Reliability
  • Case Study: Challenges in Clinical Trials Supplies for Smaller Companies
  • Vendor Management: Develop and Maintain a Successful Vendor Relationship
  • Direct – to – Patient (DTP) Distribution: Effectiveness for Multi-Location Trials
  • Cool Logistics: Ensure Cold Chain Adherence Downstream and Solid Supply Partnership
  • Into the Future: Challenges in the future and staying Ahead of the Game


Who Should Attend:

Presidents, Heads / Chiefs, Directors, VPs and Managers of:

  • Clinical Supply Chain
  • Clinical Supply Specialist
  • Clinical Operations
  • Clinical Coordination
  • Clinical Supply Planning
  • Clinical Materials
  • Clinical Logistics / Distribution
  • Clinical Purchasing
  • Clinical Packaging / Labelling
  • Clinical Manufacturing
  • Clinical Technical Specialist
  • Comparator Specialist / Sourer
  • Vendor Management / Contracting
  • Lead Processes
  • Sourcing

Key Speakers

Alena Bolazeva

Alena Bolazeva, Clinical Supply Operations, Regional Logistics Specialist, Bristol-Myers Squibb

Since joining Bristol-Myers Squibb in 2012 as Regional Logistics Specialist, Alena is supporting management of EMEA / ASIAPAC warehousing infrastructure for Clinical Trials and Expanded Access Programs in compliance with GMP, GSP, GDP and local country regulations.

Alena ‘s responsibilities in optimization of warehousing and distribution activities include distribution planning, vendor selection & qualification processes, monitoring & evaluation of vendor performance, global process improvement, issue resolution and CAPA management. She also contributes to establishing and monitoring of outsourced activities at EU Regional Hub.

Within CSO Regional Logistics, Alena is a Subject Matter Expert in storage and shipping of hazardous materials (Dangerous Goods, Cytotoxics), and in SAP (SD, MM).

Alena holds a Master degree in Supply Chain Management and has 13 years experience in various positions in Customer Service, Demand and Operations within chemical, medical devices and pharmaceutical industries.

michelleMichele Ingravallo, Director of Business Innovation and Transformation in Alliance Boots

Michele Ingravallo is responsible for driving and managing the performance of the Alcura organisation / Brand and businesses related across all the countries and divisional operation, and providing the strategic direction and support to the local operations. Also he is responsible for driving the business innovation process for all the business brands in the pharmaceutical wholesale division of Alliance Boots. He possesses European pharmaceutical experience and he has developed the strategic direction for healthcare and specialised services in the European and Chinese Markets. Michele is a graduate professor in Science, Technology and Maths. He is an MBA Candidate from the University of Bradford – School of Management. Within Alliance Boots, he has held a number of senior positions in the last 9 years where he has developed a series of clinical services for Pharmaceutical Manufacturers, hospitals and CROs. Prior to Alliance Boots, Michele held a number of senior roles in reengineering and consultancy positions in Coca Cola Company, and within the Telecommunication, Bank and the Oil sectors.

alexAlex Robertson – Senior Director, Supply Chain Management, AstraZeneca

Alex trained as a Chemist and has 27 years experience in the Pharmaceutical industry in a wide variety of roles. Alex spent the initial part of his career as a process development chemist working on wide range of projects from early development through to technology transfer and commercial establishment. During this period he also worked in pilot plant chemical manufacturing. He has experience in project management and setting up and managing global commercial stability programmes.

For a significant period Alex worked in a number of quality roles in both commercial and R&D environments. His experience in quality ranges from managing QC laboratories, Quality Management of commercial API manufacture, QA support of investigational medicinal products and Quality Management of API supply to development.

Alex recently managed the Pharmaceutical Development Sourcing group in Astrazeneca which has responsibility for managing all ‘CMC’ activities done externally to support drug development.

Alex is currently Senior Director, Supply Chain Management in AstraZeneca. This group plans and manages the end to end supply chain of materials during the drug development phase from API raw materials to final labelled packs and their distribution to Clinical study centres globally.

wolfganDr. Wolfgang Eglmeier, Witten/Herdecke University, Faculty of Health, Head Centre for Clinical Trials University Witten/Herdecke (ZKS-UW/H)

Dr. Wolfgang Eglmeier studied biology. He obtained a PhD in neuroscience in 1988. Wolfgang is working in the area of clinical development since 1988. He started as a CRA, monitoring studies in central and Eastern Europe. In the early 90s he was with a software company, which developed data management and remote data entry software. Since 1993 he holds several management positions, mainly on an European level, in the pharmaceutical industry, biotech companies and CROs (e.g. Head Clinical Research Central Europe at Novo Nordisk, Global Head Clinical Development at Paion, Head Clinical Operations Germany at Grünenthal). He has more than 25 years of experience in all aspects of clinical development, like project and study planning, performing and management of trials, data management and reporting.

After 24 years in pharmaceutical industry, biotech and CROs he returned to academia in September 2012. He heads now the ZKS-UW/H (centre for clinical trials University Witten/Herdecke).

Ian Morgan

Ian Morgan, General Manager, Sharp Clinical Services

Ian has worked in the pharmaceutical industry since 1978.

Before moving into the contracting environment Ian worked for Bayer Schering Pharmaceuticals, with headquarters in Germany. During his time at Bayer Schering he worked within Quality and Manufacturing.

Prior to his recent appointment at Sharp Clinical Services, Ian was responsible for the implementation of the Clinical Trial business for Piramal Healthcare.

Previous roles include Customer Service Director at Fisher Clinical Services, a lead provider in the Packaging, Distribution and IVRS services of Global Clinical Trials.

He has also worked at Quintiles Sciences based in Edinburgh, a clinical contract organisation. At Quintiles Ian was responsible for the Production and Distribution activities associated with Global Clinical Trials

janiceJanice Kite, MBA, MCMI, MIBC – Traceability Director Healthcare, GS1 Global Office

Prior to undertaking the assignment with GS1 Global Office to facilitate the development of process and technical Traceability standards, Janice was a senior Manager with responsibility for eBusiness for Johnson & Johnson’s UK Medical Device and Diagnostic companies. This role continued a common thread throughout her career of roles at various stages of the extended supply chain with the trend of moving downstream closer to the external customer. She has held a number of positions with medical device industry associations: ABHI and Eucomed.

Her MBA dissertation (Hypothesis: Medical Device manufacturer applied or embedded RFID has benefits to Patient Safety over existing Auto-ID technologies, e.g. Bar Codes) received critical acclaim.

ThorstonThorsten Neumann – DS Supply Chain Security Director Chair TAPA EMEA, Director, MMO Global Business Resilience / Supply Chain Security, MICROSOFT

  • Engineering Degree in Automation Technology at Flensburg University (FH)
  • žDigital Six Sigma “Green Belt???
  • žISMA Leadership program at Georgetown University
  • 16 years within Industrial Loss Prevention & Security
  • Director Global Supply Chain Security, Business Resilience & Regulatory Programs
  • BoD Member of TAPA EMEA since 2003
  • TAPA EMEA Chairman 2006 / 2007 / 2008 (partly) / 2009 / 2010 / 2011 / 2012 / 2013 / 2014
  • Industry Rep within the European Commission LandSec and ITS initiatives.
  • Industry Rep within EUROPOL, INTERPOL & TISPOL Organizations

gregEdward Greg Koski, MD, PhD – Co-Founder, President, and CEO, Alliance for Clinical Research Excellence and Safety

Internationally-recognised leader in clinical research championing a systemic approach to transforming the infrastructure of conducting clinical research globally; and a “culture of conscience” in human research, focusing on prevention of harm and quality improvement beyond regulatory compliance.

Influential in enhancing research processes domestically and internationally, including processes for accreditation of research sites and human research protections programs, certification of physician investigators, and the formation of the an industry organization for Contract Research Organizations.

  • Current Boards of Directors: SAFE-BioPharma and ACRES.
  • Senior Scientist at the Institute for Health Policy and Associate Professor of Anesthesia, Massachusetts General Hospital, Harvard Medical School.
  • First Director, Office for Human Research Protections (OHRP) at U.S. Department of Health and Human Services; created Program for International Activities within OHRP.
  • Consultant to World Health Organization (WHO) to coordinate and strengthen global mechanisms for ethical conduct of human research; and engaged with World Medical Association (WMA) on revisions of the Declaration of Helsinki.
  • Government and Multi-lateral Committee service: World Bank, WHO, Hastings Institute, Institute of Medicine (IOM), National Science and Technology Council.
  • Editorial Boards for 8 peer-review journals.
  • Faculty: Harvard Medical School, Boston University School of Medicine, Vienna (Austria) School for Clinical research; guest lecturer at Rockefeller University, UCSF, Emory, Wayne State, CHoP.
  • Keynote speaker at Conferences across Europe, Latin America, and Asia.



  • Interviews: Life Science Leader, CenterWatch, and Clinical Researcher
  • Articles: International Clinical Trials, among others
  • Peer-reviewed: Annual Reviews of Pharmacology and Toxicology
  • Clinical Therapeutics
  • Book Chapter: Human Subjects Research Regulation: Perspectives on the Future
  • (MIT Press 2014)
  • Presentations: Annual Global and domestic conferences including DIA, ACRP, and
  • Tufts Center for the Study of Drug Development; as well as international
  • regional conferences in Asia, Europe, and Latin America.
  • Complete list of Publications and Presentations available upon request.

Johan Leunen

Johan Leunen, Cargo Marketing Manager – Sales & Marketing, Brussels Airport Company

Johan Leunen initiated his career at the airport in 2000. Over a period of 10 years, Johan built experience and earned his credentials in the cargo handling industry. He first started working in the operations before moving to Customer Support and, later on, holding the function of Sales Manager. 
Johan also enriched his career as Business and Market Development Manager in the Forwarding Industry.
On May 1st, 2012, Johan joined Brussels Airport Company as Cargo Marketing Manager. Johan’s main responsibilities include offering operational support to the cargo airlines and assisting in their development at Brussels Airport. Furthermore, he also plays a key role in attracting new carriers to Brussels Airport.

John Murray

John Murray, Planning & Capability Lead, ASTRAZENECA

John trained as a Chemical Engineer and has worked for 15 years in the pharmaceutical industry in a wide variety of roles. He has international experience of working in a number of countries including UK, USA, Singapore, Puerto Rico and Sweden.

He spent the initial part of his career as an R&D Process Development Engineer. His experiences covered a broad range of Drug Substance related activities from early development in the laboratory to pilot plant and commercial manufacture scale-up. He then moved to a technical support role in Commercial Operations supporting in-line products including day- to- day support, significant process improvements and installation of new manufacturing equipment.

More recently, John gained significant experience as a Project Manager, leading CMC activities (process development, supply, regulatory) for drug development projects. This includes a diverse oncology / infection portfolio ranging from preclinical to late stage development. As a member of Global Project Teams, he helped to shape the overall drug development strategy and ensured the CMC strategy aligned with this.

John is currently Director, Planning and Capability, in R&D Supply Chain. This team manages global planning activities, Supply Chain systems, business processes and metrics for the integrated (internal / external) Supply Chain.

Mike Isles


Mike is Executive Director of the European Alliance for Access to Safe Medicines ( The EAASM is a panEuropean patient safety organisation, bringing together all concerned with eliminating falsified medicines from the supply chain. With patient safety at its heart, the EAASM is also currently championing positive change in the area of unlicensed/off-label usage of medicines which is severely compromising patients welfare and rights in certain medical conditions and situations. Mike also represents the Secretariat for the Alliance for Safe Online Pharmacy ( With over 30,000 fake pharmacy websites targeting Europe on any given day, this multisectoral organisation’s mission is to enable patients to buy their medicines online safely – where it is legal to do so. With over 50 participants involving many key internet stakeholders, its aim is to produce concrete voluntary actions that will make a real difference and ultimately benefit the health of patients and the wealth of nations. The estimated cost of counterfeit medicines to the European community is between €1-3bn per year. Mike is also European Medicines Partnership Director for International Health Partners (, a UK charity whose Queen’s Award for Enterprise for continous Innovation in 2011, recognises the tremendous humanitarian work sourcing donated quality medicines from the pharmaceutical industry and coordinating delivery via secure supply chain solutions to disaster-struck areas in close liaison with NGOs. Currently, Mike is working to expand the IHP network so that a European access to medicines platform can be developed to further harness the successful business model across a pan European landscape. Mike is also an Associate of the Ceuta Capability Group ( a consultancy that provides outsourced management expertise in healthcare. Mike’s professional background is in pharmaceuticals, where he held senior management and director positions covering sales, marketing, commercial and supply chain in a 32 year career.

Day 1

08:00 – 09:00Registration & Coffee

08:45- 09:00 Chairperson’s Opening Remarks

Keynote Presentation

09:10 – 10-00Beyond Silos: How Systems Thinking Will Save the Pharmaceutical Industry

Dr. Greg Koski, PhD, MD, President and CEO, Alliance For Clinical Research Excellence and Safety (ACRES), Senior Scientist, Mongan Institute for Health Policy, HARVARD MEDICAL SCHOOL


10:00 – 10:50 Direct – Patient (DTP) Distribution: How Effective Is This Approach in Multi – Location Trials?

  • What market trends are driving companies to the DTP distribution method?
  • What are the advantages and challenges of patient home delivery?
  • How has the rise of the orphan drug market increase opportunities for direct – to – patient logistics firms and and how has this steered the logistics industry?

Joaquin Campbell, Head, Global Clinical Trial Support, Alliance Boots

10:50 – 11:30Morning Break & Networking


11:30 – 12:20Packaging and Distribution Management of High Recruiting Flu Vaccine Clinical Study

  • Study Design
  • Removal of Expiry dates from IMP
  • Interaction with IRT system and Product Release
  • Distribution set – up and Management of Cold Chain Process
  • Resources
  • Study Close Out and Documentation

Ian Morgan, General Manager, Sharp Clinical Services


12:20 – 13:10 – GS1 Standards: Foundation to Regulatory Compliance and Improving the Efficiency of Your Supply Chain

  • Daily interaction is natural and unnoticed
  • The latest in GS1 developments
  • Enabling regulatory compliance, supply chain security and patient safety

Janice Kite, Traceability Director Healthcare, GS1

13:10 – 14:10Networking Lunch


14:10 – 15:00Life After the Falsified Medicines Directive – Opportunities and Threats

Mike Isles, Executive Director, The European Alliance for Safe Access to Medicines


15:00 – 15:50Security Measures: What Are Some Of The Measures Taken by the Supply Chain to Provide Services in a Safe Manner With High Security and Reliability

  • An overview of TAPA as an organisation
  • The members and their fight against crime
  • What is holistic supply chain security and how can this prevent the three buckets of threats
  • Cargo theft and diversion, counterfeiting, and Economically Motivated adulteration
  • How collaboration amongst supply chain partners improve security in the supply chain

Laurence Brown, Executive Director, Transported Asset Protection Association EMEA

15:50 – 16:30Afternoon Break & Networking


16:30 – 17:10 – Planning Ahead: How Timely and Accurate Forecasting and Supply Planning Affect the Supply Chain and How Can Companies Avoid Supply Delays?

  • How can companies integrate strategies and technology to ensure supply reaches the location in a timely and safe manner?
  • How to keep supply planning strategies in line with increasingly complex clinical trial designs?
  • How to harness effective forecasting to estimate wastage, overage and supply?

John Murray Brown, Planning & Capability Lead, ASTRAZENECA

17:20 – 18:10Into the Future: What will change in the future for Clinical Trials Logistics and How Should Companies Evolve to Stay Ahead of the Game?

  • How the balance of power is shifting along the clinical supply chain and what must companies look out for?
  • What technologies and strategies can we expect to see on the horizon?
  • Will these technologies and strategies forecast a bright future?


  • Joaquin Campbell, Head, Global Clinical Trial Support, Alliance Boots

18:10 Chairperson’s Closing Remark & End of Day 1


Day 2

08:00 – 08:45Registration & Coffee

08:45 – 09:00Chairperson’s Opening Remarks


09:00 – 09:50Economic Outlook: How Can Supply Chain Logistics Steer the Clinical Trials Industry and What Must Companies Do to Remain Competitive?

  • How can the outsourcing of clinical trial activities to clinical research organisation (CROs) improve the supply chain logistics for clinical trials?
  • How economic prosperity in Asia impacts the focus of clinical trials supply chain logistics into the region?
  • How can the West compete with Asia or would it make more sense to continue driving clinical trial operations in Asia and how can supply chain logistics facilitate the development of clinical trials in Asia?

Dr. Wolfgang Eglmeier, Head ZKS-UW/H (Centre for Clinical Studies Univeristy Witten / Herdecke), Faculty for Health, University Witten / Herdecke


09:50 – 10:40Vendor Management: What Does It Take to Develop and Maintain a Successful and Save Vendor Relationship?

  • Importance of negotiating and drafting clear agreements to avoid pitfalls
  • What are some of the ways to establish a mutually agreeable approach for both parties?
  • How can you retain sufficient control with effective feedback channels and data monitoring?

Alena Bolazeva, Specialist, CSO Regional Logistics – Research & Development, Bristol – Myers Squibb

10:40 – 11:20Morning Break & Networking


11:10 – 11:50Cool Logistics: What Efforts Should Be Taken to Ensure Cold Chain Adherence Downstream and Solid Supply Chain Partnerships?

  • What are some of the ways to mitigate risk throughout the cold chain to ensure products arrive in peak condition?
  • How will the strengthening of manufacturer and logistics provider ensure patient safety?

Johan Leunen, Cargo Marketing Manager – Sales Marketing, Brussels Airport Company

Panel Discussion:

11:50 – 12:40Global Clinical Trial Landscape: How Does the Globalisation of Clinical Trials Increases the Complexity of Supply Chain Logistics?

  • With most clinical trials being conducted in emerging markets, can this address the escalating costs of drug development and market competition?
  • How can companies address wide spread differences from country to country in customs knowledge, experience and laws which may affect quality standards in the clinical trials universe?
  • With the evolving regulatory requirements in developing countries, how can clinical trials be conducted especially with the increasing protection of research subject?


  • Alex Robertson, Senior Director, Supply Chain Management, AstraZeneca
  • Dr. Wolfgang Eglmeier, Head ZKS-UW/H (Centre for Clinical Studies University Witten / Herdecke), Faculty for Health University Witten / Herdecke

12:40 – 13:40Networking Lunch

Post Conference Workshop:

13:40 – 17:10Vendor Management – Outsourcing in Clinical Trials

  • Addressing the sponsor – vendor relationship
  • Analysis of critical aspects
  • Uncovering best practices
  • Management of costs
  • Dr. Wolfgang Eglmeier, Head ZKS-UW/H (Centre for Clinical Studies University Witten / Herdecke), Faculty for Health University Witten / Herdecke

17:30Chairperson’s Closing Remark & End of Conference



sharp-clinicalSharp Clinical Services is a leading provider of specialist clinical supply chain services, from drug product development and manufacturing services through to increasingly complex clinical supplies packaging, clinical labeling and clinical distribution services.

Our experienced project management and operational teams bring together years of unparalleled experience in producing and managing your clinical supply chain across the globe. All projects are compliant with the highest quality standards spanning Good Manufacturing Practices (cGMP), Good Distribution Practices, and all international regulatory requirements.

With Sharp Clinical Service’s experience of managing local and global clinical supply chains, access to the world markets just became easier from clinical production, labeling & distribution to comparator sourcing & EU Qualified Person (QP) audit and release services. We are big enough to deliver your global project while remaining small enough to care for your product like our own.

Value Added Services

  • Clinical Supply Chain Optimisation
  • QP Consultancy
  • Project Management
  • Design Engineering
  • Kit/Tooling Design
  • Primary/Secondary Packaging Consultation
  • Protocol Review and Breakdown
  • Import/Export Consultation/Assistance
  • International Shipping Consultation
  • Study Design
  • Drug Forecasting
  • Validation Studies Design
  • Stability Protocol creation
  • R&D Specifications
  • Formulation selection
  • Formula Development Consultation


Almac Group

The Almac Group is an established contract development and manufacturing organization that provides an extensive range of integrated services to over 600 companies globally within the pharmaceutical and biotech sectors. The services range from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply, IXRS® technology (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organization that has organically grown over 30 years and now employs in excess of 3,500 highly skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with operations across the US (Pennsylvania, North Carolina and California) and in Asia (Singapore and Tokyo).
For more information visit or e-mail


B&C Group

B&C Group has developed a wide range of specialized Clinical Trial Supply services to ensure the successful conduct of your clinical trials.
These services include drug Sourcing, Primary & Secondary packaging & Labeling, Qualified Person expertise, sample collection Kit assembly, Warehousing & Distribution, Transport and Storage or Archiving of clinical trial material and biological specimens. Through our unique combination of services and global coverage (global depot network in 18 countries across the 5 continents), we offer efficient and tailor-made solutions to support the full clinical supply chain.
B&C group is also your preferred partner for centralized biological sample management, biorepository and biobanking activities.



PCI is the global leader for drug development services, supporting our customers in each stage of the development and commercialization of drug products. A trusted partner to the world’s largest and most successful pharmaceutical firms, offer services from preclinical development, early phase clinical studies through large scale Phase III/IV, commercial launch, and ongoing supply. We partner with pharmaceutical and biotech firms, offering insight and expertise, combined with innovative technologies and an uncompromising commitment to exceptional service and quality.


Media Partners

PharmaVOICE magazine provides commentary about the challenges and trends impacting the life-sciences industry, covering a range of issues from molecule through market. PharmaVOICE’s more than 25,000 BPA-qualified subscribers are also kept abreast of the latest trends through additional media resources, including WebSeminars, Podcasts, Videocasts, and White Papers. For further information please visit:

Biocompare is the most comprehensive, in-depth, and objective website for life science product information. Thousands of scientists use Biocompare daily to quickly find the right product for their experiments rather than looking through multiple print catalogs. Visit to find the products you need, stay informed of new technologies, read product reviews, watch product videos, and keep up-to-date on life science news. For further information please visit:

European Life Science is the premier journal devoted to presenting outstanding research and researchers within the life science fields. For further information please visit: is the leading online product and application publication for laboratory scientists featuring the latest news, application articles, videos, product directory and product reviews. Membership is fast, free and provides access to all of the SelectScience services. is a unique video news channel for laboratory application and product information. For further information please visit:

InPharm is the online platform for exclusive pharmaceutical news, comment, contracts, services, jobs and events and is home to, Pharmafile and Pharmafocus. For further information please visit: is the leading industry-sponsored portal for the pharmaceutical sector. Supported by most of the leading pharmaceutical corporations, provides dynamic real-time news, features, events listings and international jobs to industry professionals across Europe and the US. For further information please email:

BIOTECHNOLOGY EUROPE is owned by BIOTECHNOLOGY WORLD. It is based and located in Warsaw, Poland. Biotechnology World was founded in 2007 to provide the world’s biotech and pharma information and market to make it universally accessible and useful for scientific and business processes. Its first step to fulfilling that mission was building the BIOTECHNOLOGY EUROPE platform that will allow a quick spread of information in different channels. BIOTECHNOLOGY EUROPE offers companies completed internet public relations, publication and marketing solutions. One of the mains goals of BIOTECHNOLOGY EUROPE is to integrate the Biotech and Pharma Sector in Europe to global biotechnology, pharmaceutical and life science activities. For further information please visit

Future Pharmaceuticals has forged powerful relationships with key industry leaders to provide a platform for successful brand recognition, and for senior decision- makers to have the means to procure and plan implementation strategies based on the topics covered. Positioned to be an authoritative resource within top pharma companies as well as small, specialty, and biotech, Future Pharmaceuticals magazine is geared to create a deep penetration into a highly targeted and responsive audience, bridging the gap between the industries’ top issues and the solutions top-tier vendors can provide. For further information please visit: